Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Rating of “Reduce” by Brokerages

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have earned an average recommendation of “Reduce” from the nine brokerages that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating and eight have issued a hold rating on the company.

Separately, The Goldman Sachs Group assumed coverage on shares of Bayer Aktiengesellschaft in a report on Thursday, May 30th. They set a “neutral” rating for the company.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS:BAYRY opened at $7.81 on Friday. The firm has a 50 day moving average of $7.25 and a 200-day moving average of $7.42. Bayer Aktiengesellschaft has a 12 month low of $6.82 and a 12 month high of $13.89. The company has a current ratio of 1.31, a quick ratio of 0.87 and a debt-to-equity ratio of 1.06. The stock has a market capitalization of $30.69 billion, a PE ratio of -8.98 and a beta of 1.04.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.25 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.25. Bayer Aktiengesellschaft had a negative net margin of 6.70% and a positive return on equity of 17.57%. The company had revenue of $12 billion during the quarter. On average, equities research analysts predict that Bayer Aktiengesellschaft will post 1.35 EPS for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.